Alzheimer's Disease

Atlanta, GA

54 Alzheimer's Disease Trials near Atlanta, GA

Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Buntanetap for Alzheimer's Disease

Decatur, Georgia
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 85

760 Participants Needed

AR1001 for Alzheimer's Disease

Decatur, Georgia
This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90

1150 Participants Needed

Donanemab for Alzheimer's Disease

Decatur, Georgia
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:65 - 80

2996 Participants Needed

KarXT for Psychosis in Alzheimer's Disease

Atlanta, Georgia
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90

406 Participants Needed

ALZ-801 for Early Alzheimer's Disease

Decatur, Georgia
This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 85

163 Participants Needed

KarXT for Alzheimer's-Related Psychosis

Decatur, Georgia
This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90

400 Participants Needed

Remternetug for Alzheimer's Disease

Decatur, Georgia
This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85

1667 Participants Needed

Donanemab for Early Alzheimer's Disease

Decatur, Georgia
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85

1736 Participants Needed

KarXT for Alzheimer's-Related Psychosis

Decatur, Georgia
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026 or CN012-0027. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 or CN012-0027 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90

300 Participants Needed

VY7523 for Alzheimer's Disease

Decatur, Georgia
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 18 months for the highest dose group.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50 - 90

52 Participants Needed

ACU193 for Early Alzheimer's Disease

Decatur, Georgia
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 90

540 Participants Needed

Xanamem for Alzheimer's Disease

Decatur, Georgia
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+

220 Participants Needed

GSK4527226 for Early Alzheimer's Disease

Decatur, Georgia
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85

367 Participants Needed

ONO-2020 for Alzheimer's Disease

Decatur, Georgia
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 85

240 Participants Needed

BMS-986368 for Alzheimer's Disease

Decatur, Georgia
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:55 - 90

120 Participants Needed

Mevidalen for Alzheimer's Disease

Decatur, Georgia
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80

300 Participants Needed

Benfotiamine for Alzheimer's Disease

Atlanta, Georgia
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 89

406 Participants Needed

ABBV-916 for Early Alzheimer's Disease

Decatur, Georgia
This trial is testing a new drug called ABBV-916 to see if it can help people aged 50-90 who are in the early stages of Alzheimer's disease. Participants will receive the drug regularly over several months. The study aims to find out if the drug is safe and effective by monitoring changes in symptoms and side effects.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 90

106 Participants Needed

PMN310 for Alzheimer's Disease

Decatur, Georgia
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+

128 Participants Needed

NMRA-323511 for Agitation in Alzheimer's Disease

Atlanta, Georgia
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment. Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:55 - 90

96 Participants Needed

Why Other Patients Applied

"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

OF
Alzheimer's Disease PatientAge: 65

"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

AH
Dementia PatientAge: 64

"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

WU
Healthy Volunteer PatientAge: 76

"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

VL
Alzheimer's PatientAge: 71

"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

EK
Mild Cognitive Impairment PatientAge: 72

LY3954068 for Alzheimer's Disease

Decatur, Georgia
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. The study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period. If the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:50 - 85

32 Participants Needed

ADEL-Y01 for Alzheimer's Disease

Decatur, Georgia
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI due to AD and mild AD in Part 2. The study includes 2 parts: Part 1 (single ascending dose \[SAD\] and Part 2 (multiple ascending dose \[MAD\]).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

73 Participants Needed

MK-2214 for Alzheimer's Disease

Decatur, Georgia
This trial is testing a new drug called MK-2214 to see if it is safe and how it behaves in the body. It targets adults with early memory and thinking problems, like mild cognitive impairment or mild-to-moderate Alzheimer's Disease. Researchers want to know if the drug reaches helpful levels in the brain fluid and stays there long enough to potentially help these conditions.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:50 - 80

48 Participants Needed

LY4006895 for Alzheimer's Disease

Decatur, Georgia
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:45 - 85

68 Participants Needed

Music for Alzheimer's Disease Prevention

Atlanta, Georgia
The goal of this clinical trial is to test the benefits of beat-accented music stimulation (BMS) for behavioral changes of physical activity (PA) in older adults with subjective memory complaints. Specific Aims are to determine (1) whether BMS beneficially influences PA behaviors and psychological responses to PA in older adults for 6 months, and (2) whether exercising with BMS differently influences physical and cognitive functioning as well as quality of life in older adults.To test the effects of BMS on PA, participants will be randomly assigned to an exercise intervention that either includes BMS or does not include BMS. Participants will attend a supervised group strength training (ST) (30 min/day) and and aerobic exercise (AE) (30-50 min/day) session for 3 days/week for the first 2 months, 1 day/week for the next 2 months (while encouraging participants to independently perform both AE and ST on other days), and independently for the final 2 months (always with a goal of performing \>150min/week AE and 3 days/week of ST for 30 min/day).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

80 Participants Needed

Sensory Stimulation for Alzheimer's Disease

Atlanta, Georgia
This trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 90

600 Participants Needed

Treadmill Training for Mild Cognitive Impairment and Alzheimer's Disease

Atlanta, Georgia
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects of MCI and AD on locomotor adaptation and walking function.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:50 - 90

10 Participants Needed

Sensory Stimulation for Alzheimer's Disease

Decatur, Georgia
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:50 - 92

402 Participants Needed

Citicoline Supplement for Mild Cognitive Impairment

Atlanta, Georgia
This trial is testing whether a citicoline supplement can help people with mild cognitive impairment (MCI). Citicoline may improve brain function by increasing important brain chemicals. Researchers will also check if it affects sleep and markers related to Alzheimer's disease. Citicoline has been studied for its potential benefits in cognitive decline, including Alzheimer's disease and vascular cognitive impairment.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:60+

100 Participants Needed

Citicoline Supplement for Alzheimer's Disease

Atlanta, Georgia
This trial is testing whether a citicoline supplement can help people with Alzheimer's Disease sleep better and think more clearly. Citicoline may boost brain chemicals that are important for memory and sleep. Citicoline has been extensively used for the treatment of neurodegenerative disorders associated with head trauma, stroke, brain aging, cerebrovascular pathology, and Alzheimer's disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

20 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Alzheimer's Disease clinical trials in Atlanta, GA pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Alzheimer's Disease clinical trials in Atlanta, GA work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Alzheimer's Disease trials in Atlanta, GA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Atlanta, GA for Alzheimer's Disease is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Atlanta, GA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Alzheimer's Disease medical study in Atlanta, GA?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Alzheimer's Disease clinical trials in Atlanta, GA?

Most recently, we added Treadmill Training for Mild Cognitive Impairment and Alzheimer's Disease, BMS-986368 for Alzheimer's Disease and ONO-2020 for Alzheimer's Disease to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Georgia

Anxiety Clinical Trials in Georgia

Schizophrenia Clinical Trials in Georgia

ADHD Clinical Trials in Georgia

Bipolar Disorder Clinical Trials in Georgia

Multiple Sclerosis Clinical Trials in Georgia

Autism Clinical Trials in Georgia

Treatment Resistant Depression Clinical Trials in Georgia

Borderline Personality Disorder Clinical Trials in Georgia

Social Anxiety Disorder Clinical Trials in Georgia

Parkinson's Disease Clinical Trials in Georgia

Alzheimer's Disease Clinical Trials in Georgia

By Location

Clinical Trials near Atlanta, GA

Clinical Trials near Augusta, GA

Clinical Trials near Decatur, GA

Clinical Trials near Savannah, GA

Clinical Trials near Marietta, GA

Clinical Trials near Columbus, GA

Clinical Trials near Macon, GA

Clinical Trials near Gainesville, GA

Clinical Trials near Lawrenceville, GA

Clinical Trials near Athens, GA

Clinical Trials near Roswell, GA

Clinical Trials near Stockbridge, GA

Other People Viewed

By Subject

193 Clinical Trials near Atlanta, GA

184 Clinical Paid Trials near Atlanta, GA

18 Parkinson's Disease Trials near Atlanta, GA

23 Schizophrenia Trials near Atlanta, GA

62 Depression Trials near Atlanta, GA

89 Alzheimer's Disease Trials near Boston, MA

22 Alzheimer's Disease Trials near Vancouver, WA

126 Clinical Trials near Ankeny, IA

Top Alzheimer's Disease Clinical Trials near Albuquerque, NM

Top Clinical Trials near Decatur, GA

Top Alzheimer's Disease Clinical Trials near Columbia, SC

Top Alzheimer's Disease Clinical Trials near Charleston, SC

By Trial

2-HOBA for Alzheimer's Disease

ExAblate BBB Disruption for Alzheimer's Disease

Memantine for Brain Tumor

Sleep + Cognitive Training for Cognitive Impairment

Trimodulin for Severe Community-acquired Pneumonia

Brain Activity Monitoring for Parkinson's Disease Speech Impairment

SIM0500 for Multiple Myeloma

TENS Unit for Pain After Abortion

NTS-WBRT vs. HA-WBRT for Brain Cancer

Mindfulness Intervention for HIV and Chronic Pain

Imaging with Zirconium Zr 89 Crefmirlimab Berdoxam for Cancer

Imaging Systems for Retinal Disease

Related Searches

Top Alzheimers-disease Clinical Trials near Charleston, SC

Top Alzheimers-disease Clinical Trials near Cleveland, OH

Top Alzheimers-disease Clinical Trials near Denver, CO

Top Prostate-cancer Clinical Trials near Austin, TX

Cefazolin + Ertapenem for Staph Bacteremia

Reentry Program for HIV/AIDS

Briquilimab for Chronic Hives

Psilocybin for Depression in Autism

Adoptive T Cell Therapy and Vaccines for Medulloblastoma

Virtual Reality for Anxiety

Amivantamab + Lazertinib + Chemotherapy for Non-Small Cell Lung Cancer

Support and Intervention for Latiné Prostate Cancer Survivors

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial